Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: A retrospective analysis and definition of response criteria

Pediatric Blood and Cancer

Volumn 49, Issue 5, 2007, Pages 629-633

  Bergstraesser, Eva ^a   Hasle, Henrik ^c   Rogge, Tim ^b   Fischer, Alexandra ^b   Zimmermann, Martin ^d   Noellke, Peter ^b   Niemeyer, Charlotte M ^b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chemotherapy; Juvenile myelomonocytic leukemia; Response criteria; Treatment

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; CYTARABINE; ETOPOSIDE; ISOTRETINOIN; MERCAPTOPURINE; PURINE DERIVATIVE; RETINOID; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKOCYTE COUNT; LIVER SIZE; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY; SPLEEN SIZE; THROMBOCYTE COUNT; TREATMENT OUTCOME; BLOOD CELL; CHRONIC MYELOMONOCYTIC LEUKEMIA; COMPARATIVE STUDY; DRUG EFFECT; DRUG SCREENING; LIVER; ORGAN SIZE; SPLEEN;

ANTINEOPLASTIC AGENTS; BLOOD CELLS; DRUG EVALUATION; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LEUKOCYTE COUNT; LIVER; ORGAN SIZE; PLATELET COUNT; RETROSPECTIVE STUDIES; SPLEEN; TREATMENT OUTCOME;

EID: 35148867031     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21038     Document Type: Article

References (39)

1. Niemeyer C, Locatelli F. Chronic myeloproliferative disorders. In: Pui C-H, editor. Childhood Leukemias, 2nd edn. New York: Cambridge University Press; 2006. pp 571-598.
2. Emanuel PD. Juvenile myelomonocytic leukemia. Curr Hematol Rep 2004;3:203-209.
3. Niemeyer CM, Aricò M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: A retrospective analysis of 110 cases. Blood 1997;89:3534-3543.
4. Tartaglia M, Niemeyer CM, Song X, et al. PTPN11 mutations in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003;34:148-150.
5. Locatelli F, Nöllke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): Results of the EWOG-MDS/EBMT trial. Blood 2005;10:410-419.
6. Lilleymann JS, Harrison JF, Black JA. Treatment of juvenile chronic myeloid leukemia with sequential subcutaneous cytarabine and oral mercaptopurine. Blood 1977;49:559-562.
7. Mutz ID, Zoubek A. Transient response to alpha-interferon in juvenile chronic myelomonocytic leukemia. Pediatr Hematol Oncol 1988;5:71-75.
8. Chan HSL, Estrov Z, Weitzman SS, et al. The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia. J Clin Oncol 1987;5:1960-1967.
9. Woods WG, Barnard DR, Alonzo TA, et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: A report from the Children's Cancer Group. J Clin Oncol 2002;20:434-440.
10. Castleberry RP, Emanuel PD, Zuckerman KS, et al. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med 1994;331:1680-1684.
11. Castleberry RP, Loh ML, Jayaprakash N, et al. Phase II window study of the farnesyltransferase inhibitor R115777 (Zarnestra®) in untreated juvenile myelomonocytic leukemia (JMML): A Children's Oncology Group Study. Blood 2005; 106:727a (abstract).
12. Ritter J, Creutzig U, Schellong G. Treatment results of three consecutive German childhood AML trials: BFM-78, -83, and -87. AML-BFM-Group. Leukemia 1992; 59-62.
13. Creutzig U, Ritter J, Zimmermann M, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: Results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Muenster 93. J Clin Oncol 2001;19:2705-2713.
14. Lie SO, Jonmundsson G, Mellander L, et al. A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: Best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol 1996;94:82-88.
15. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia 2000;14: 2205-2222.
16. Gustafsson G, Kreuger A, Clausen N, et al. Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non-high-risk patients: The Nordic experience of 2648 patients diagnosed between 1982 and 1996. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Acta Paediatr 1998;87:1151-1161.
17. Mann HB, Whitney DR. On a test of whether one or two random variables is stochastically larger than the other. Ann Math Stat 1947;18:50-60.
18. Kruskal WH, Wallis WA. Use of ranks in one criterion variance analysis. J Am Stat Assoc 1952;47:583-621.
19. Spearman C. The proof and measurement of association between two things. Am J Psychology 1904;15:72-101.
20. Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: The Bonferroni vs. Holm methods. Am J Public Health 1996;86:726-728.
21. Castro-Malaspina H, Schaison G, Passe S, et al. Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Clinical and hematological observations and identification of prognostic factors. Cancer 1984;54:675-686.
22. Lutz P, Zix-Kieffer I, Souillet G, et al. Juvenile myelomonocytic leukemia: Analyses of treatment results in the EORTC Children's Leukemia Cooperative Group (CLCG). Bone marrow transplant 1996;18:1111-1116.
23. Cooke JV. Chronic myelogenous leukemia in children. J Pediatr 1953;42:537-550.
24. Bernard J, Seligmann M, Acar J. La leucémie myéloide chronique de 1'enfant. Étude de vingt observation. Arch Fr Pediatr 1962;19: 881-894.
25. Reisman LE, Trujillo JM. Chronic granulocytic leukemia of childhood. J Pediatr 1963;62:710-721.
26. Hardisty RM, Speed DE, Till M. Granulocytic leukaemia in childhood. Br J Haematol 1964;10:551-566.
27. Laver J, Kushner BH, Steinherz PG. Juvenile chronic myeloid leukemia: Therapeutic insights. Leukemia 1987;10:730-733.
28. Arico M, Nespoli L, Caselli D, et al. Juvenile chronic myeloid leukaemia and alpha-interferon. Eur J Pediatr 1989;148:379-380.
29. Mirro J, Dow LW, Kalwinsky DK, et al. Phase I-II study of continuous-infusion high-dose human lymphoblastoid interferon and the in vitro sensitivity of leukemic progenitors in nonlymphocytic leukemia. Cancer Treat Rep 1986;70:363-367.
30. Hazani A, Barak Y, Berant M, et al. Congenital juvenile chronic myelogenous leukemia: Therapeutic trial with interferon-alpha-2. Med Pediatr Oncol 1993;21:73-76.
31. Suttorp M, Rister M, Schmitz N. Interferon-alpha-2 (IFN) plus hydroxyurea for treatment of juvenile chronic myelogenous leukemia. Med Pediatr Oncol 1994;22:358-359.
32. Maybee D, Dubowy R, Krischer J, et al. Unusual toxicity of high dose alpha interferon (αIFN) in the treatment of juvenile chronic myelogenous leukemia (JCML). Proc Am Soc Clin Oncol 1992;11: 950 (abstract).
33. DeHeredia CD, Ortega J J, Coll MT, et al. Results of intensive chemotherapy in children with juvenile chronic myelomonocytic leukemia: A pilot study. Med Pediatr Oncol 1998;31: 516-520.
34. Festa RS, Shende A, Lanzkowsky P. Juvenile chronic myelocytic leukemia: Experience with intensive combination chemotherapy. Med Pediatr Oncol 1990;18:311-316.
35. Hasle H, Kerndrup G, Yssing M, et al. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. Leukemia 1996;10:1269-1273.
36. Emanuel PD, Bates LJ, Zhu SW, et al. GM-CSF dysregulation in juvenile chronic myelogenous leukemia. Blood 1990;76:267a (abstract).
37. Pui CH, Arico M. Isotretinoin for juvenile chronic myelogenous leukemia. N Engl J Med 1995;332:1520-1521.
38. Castleberry RP, Chang M, Maybee D, et al. A phase II study of 13-cis retinoic acid (CRA) in juvenile myelomonocytic leukemia (JMML). A Pediatric Oncology Group (POG) study. Blood 1997; 90:364a (abstract).
39. Lauchle JO, Braun BS, Loh ML, et al. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatr Blood Cancer 2005;46:579-585.